Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Leucine+Isoleucine" patented technology

Protective composite amino acid composition for kidney and its use

InactiveCN1439364AProtectiveProtects against oxidative phosphorylationPeptide/protein ingredientsUrinary disorderDiseaseThreonine
A compound amino acid composition for protecting the kidney contains glycine, alpha-alanine, threonine, serine, leucine, isoleucine, proline, etc, and can be used to prepare the medicine in the form injection, powder, tablet, or capsule for treating the acute renal dysfunction caused by cisplatin medicines and ischemia. Its advantage is high curative effect.
Owner:ZHEJIANG UNIV +1

Alcohol dehydrogenase mutant and use thereof

The invention discloses an alcohol dehydrogenase mutant and a use thereof. The alcohol dehydrogenase mutant is shown in the formula (1) and / or (2). (1) Phenylalanine at 147th of an amino acid sequenceshown in the formula of SEQ ID NO.1 is replaced by leucine, isoleucine, methionine or cysteine. (2) Alanine at 202th of the amino acid sequence shown in the formula of SEQ ID NO.1 is replaced with leucine, isoleucine or valine. A semi-rational design is used to modify the alcohol dehydrogenase LkADH derived from Lactobacillus kefir so that a plurality of alcohol dehydrogenase mutants are obtained. The alcohol dehydrogenase mutant has the characteristics of high enzyme activity, can efficiently catalyze t-butyl 6-chloro-3, 5-dicarbonylcaproate to prepare t-butyl (S)-6-chloro-5-hydroxy-3-carbonylcaproate and has a great significance for the production of statin drug intermediates.
Owner:ZHEJIANG UNIV

Cyclic peptide for treating cancer

The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val (SEQ ID NO: 5), Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 9), and X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4 (SEQ ID NO: 10). The amino acids X1, X2, X3, and X4 can be each independently valine, leucine, isoleucine, or alanine; X5 can be glycine, alanine, leucine, isoleucine, or valine; X6, X7, X8, and X9 can be each independently glutamic acid or asparagine; X10 can be lysine or arginine; X11 can be methionine or cysteine; and X12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).
Owner:SAINT LEO UNIVERSITY

Nonamer Peptides for Cancer Treatment

InactiveUS20080058272A1Peptide/protein ingredientsImmunoglobulinsFibroblast activation protein, alphaTherapeutic treatment
The present invention provides nonamer peptides derived from fibroblast activation protein α (FAPα) for the treatment of solid tumors. These peptides specifically bind to HLA, defined by an IC50 value of less than about 50 μM, induce a T cell response in a subject, wherein position No. 2 of said nonamer peptide is leucine (L), isoleucine (I) or methionine (M), and position No. 9 of said nonamer peptide is leucine (L), valine (V) or isoleucine (I). Further, a composition comprising a nonamer peptide and methods for the prophylactic and therapeutic treatment are provided.
Owner:BECKER JUERGEN +2

Tetrapeptide having effect of inhibiting VEGF-induced angiogenesis and use thereof

Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.
Owner:AVIXGEN

Antibacterial peptide LJ-2 and application thereof

The invention discloses an antibacterial peptide LJ-2 and an application thereof. The amino acid sequence of the antibacterial peptide LJ-2 is as follows: the amino acid sequence of the antibacterialpeptide LJ-2 is shown in the specification: arginine, arginine, valine, leucine, arginine, isoleucine, leucine, lysine, histidine, histidine, glutamine, glycine, leucine, isoleucine, arginine, asparagine, leucine and leucine; the antibacterial peptide LJ-2 has good antibacterial activity on gram-positive bacteria, gram-negative bacteria and fungi, and has the advantages of low hemolysis, heat resistance, salt resistance, acid and alkali resistance and repeated freeze thawing resistance. Therefore, the antibacterial peptide LJ-2 disclosed by the invention has a wide application prospect in thefields of anti-infective drug preparation, animal husbandry development, human disease prevention and treatment, food preservation, detergents, cosmetics and the like.
Owner:HENAN INST OF SCI & TECH +1

Direct vat set acetic acid bacteria leavening agent as well as preparation method and application thereof

The invention relates to a direct vat set acetic acid bacteria leavening agent and a preparation method and application thereof. The direct vat set acetic acid bacteria leavening agent is prepared from acetic acid bacteria and a protective agent, the protective agent comprises skimmed milk powder and amino acid, and the amino acid comprises leucine, isoleucine and valine. According to the invention, the skimmed milk powder, leucine, isoleucine and valine are creatively combined as a protective agent for acetic acid bacteria, and the four components cooperate with each other and have synergistic interaction, so that the destructive effect of ice crystal formation on thalli and the damage of dehydration drying on thalli and enzyme activity in the freeze-drying process can be reduced, the activity of acetic acid bacteria is better protected, the survival rate in the freeze-drying process is improved, and the viable count of acetic acid bacteria in the prepared leavening agent is increased. The direct vat set acetic acid bacteria leavening agent provided by the invention has important application value in preparation of fermented beverages or fermented seasonings.
Owner:JIANGSU WECARE BIOTECHNOLOGY CO LTD

Aliphatic amino acid biosynthesis inhibitors and a method of synthesizing the same

The embodiments herein provide a composition and a method of synthesizing a composition comprising an aliphatic amino acid biosynthesis inhibitor having an antifungal activity. The composition comprises 2-oxo-2H-chromen-7-yl propiolate, diethyl-hex-2-en-4-yne-dioate and dinonyl-hex-2-en-4-yne-dioate. The composition inhibits a biosynthesis of an aliphatic amino acid in a fungal biological system. The aliphatic amino acid is selected from a group consisting of leucine, isoleucine and valine. The composition is used with a concentration of 0-200 μg / ml. The method comprises mixing solutions of dicyclohexylcarbodiimide (DCC) and Dimethylaminopyridine (DMAP) with alcohol, acetylene carboxylic acid and dichloromethane to obtain a mixture which is stirred filtered and washed with ether. The solvents are evaporated to obtain a residue that is dissolved in dichloromethane and stirred with a catalyst. The extra solvents are evaporated to obtain the derivative compound and purified by silica gel column chromatography.
Owner:SARDARI SOROUSH +3

Anti-tumor grifola frondosa glycoprotein as well as preparation method and application thereof

The invention belongs to the technical field of biological medicine, and discloses anti-tumor grifola frondosa glycoprotein as well as a preparation method and application thereof. The protein content of the anti-tumor grifola frondosa glycoprotein is 54.0 + / -3.0%, the polysaccharide content of the anti-tumor grifola frondosa glycoprotein is 20.3 + / -2.0%, the weight-average molecular weight of the anti-tumor grifola frondosa glycoprotein is 17.5 kDa, and the monosaccharide composition and the molar ratio of fucose to glucosamine hydrochloride to galactose to glucose to mannose to galacturonic acid to glucuronic acid are 2.4: 0.8: 3.9: 72.3: 7.7: 3.2: 9.6. The amino acids are composed of alanine, glycine, threonine, valine, leucine, isoleucine, proline, asparaginic acid, phenylalanine, tyrosine and glutamic acid. The grifola frondosa glycoprotein disclosed by the invention has the effects of enhancing immune response of a tumor body and inhibiting in-vivo growth of breast cancer through in-vivo verification.
Owner:GUANGDONG INST OF MICROBIOLOGY GUANGDONG DETECTION CENT OF MICROBIOLOGY

The ctl epitope of hepatitis B virus core antigen and its related application

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.
Owner:海图生物科技(上海)有限责任公司 +1

Composition for treating diabetes mellitus and diabetes analysis method

The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components. The composition will be more effective when leucine, isoleucine, or valine is included as branched-chain amino acids, and metformin as the biguanide derivative.
Owner:KATO YASUMASA

Preparation method of branched chain amino acid chelated copper

The invention discloses a preparation method of branched chain amino acid chelated copper. The preparation method of the branched chain amino acid chelated copper comprises the following steps: adding raw materials into a high-pressure reaction kettle; heating the high-pressure reaction kettle to obtain a reaction solution; putting the reaction solution into a crystallization kettle for cooling crystallization; centrifuging and drying the crystallization liquid; crushing the dried product, and sterilizing the crushed product in a sterilization box; packaging to obtain the food-grade branched chain amino acid copper, wherein the branched chain amino acid is food-grade valine, leucine, isoleucine and a mixture of the food-grade valine, leucine and isoleucine. The preparation method has the beneficial effects that branched chain amino acids are food-grade valine, leucine, isoleucine and a mixture thereof, a copper source is food-grade copper hydroxide, copper oxide and a mixture of the food-grade copper hydroxide and copper oxide, stirring, mixing and high-temperature heating are carried out in a high-pressure reaction kettle, cooling crystallization, centrifugal drying and sterilization operations are adopted for post-treatment, the process is fine and perfect, and the quality of the obtained branched chain amino acid chelated copper is high.
Owner:河北力维素科技有限公司

CTL epitope of hepatitis B core antigen and related application of CTL epitope

The invention relates to the field of biological medicine, in particular to hepatitis B virus T epitope peptide which can be used for effectively treating hepatitis B and various complications, and cutting off placental infection to a fetus and milk-born infection of hepatitis B virus to a new born child, and is based on DC cells. The amino acid sequence of the T epitope peptide is QLFHLZLIX (glutamine-leucine-phenylalanine-histidine-leucine-Z-leucine-isoleucine-X), wherein X and Z are optional amino acids.
Owner:海图生物科技(上海)有限责任公司 +1

Application of plasma metabolite in aspect of diagnosing severity of Parkinson's disease

The invention discloses an application of a plasma metabolite in the aspect of diagnosing the severity of Parkinson's disease, and particularly relates to an application of the plasma metabolite in preparing a detection reagent or a detection substance for diagnosing the severity of Parkinson's disease. The plasma metabolite comprises plasma branched-chain amino acid and / or aromatic amino acid, the branched-chain amino acid is selected from one or a combination of three of leucine, isoleucine and valine, and the aromatic amino acid is tyrosine and / or phenylalanine. Plasma is taken as a sample, a biological sample is easy to obtain, simple and convenient to collect, large in quantity, low in price and short in detection period, the severity of the PD disease can be judged by detecting plasma markers, and the method is a reliable, efficient, convenient and fast novel method and has good application prospects in treatment and prognosis of PD patients.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Compound amino acid soluble powder and preparation method thereof

The invention belongs to the field of veterinary medicine, and discloses compound amino acid soluble powder which comprises 5-15% of compound amino acid, 10-35% of an inclusion agent, 5-10% of a stabilizer, 2-5% of a flavoring agent and 35-78% of a soluble filler, the compound amino acids comprise lysine, methionine, tryptophan, arginine, threonine, histidine, leucine, isoleucine, phenylalanine, valine, glycine and proline; the invention also discloses a preparation method of the compound amino acid soluble powder. The preparation method is used for preparing the compound amino acid soluble powder, the stability and solubility of the compound amino acid can be improved through the inclusion agent, the preparation process is simple and feasible, and large-scale industrial production is facilitated.
Owner:HEBEI KEXING PHARMA

Method for simultaneously detecting contents of leucine, isoleucine and valine in blood

PendingCN110806458AEasy to handleProcessing time saverComponent separationValineMass spectrometric
The invention provides a method for simultaneously detecting contents of leucine, isoleucine and valine in blood. The method comprises the following steps: respectively detecting at least three standard solutions by using a high performance liquid chromatography tandem mass spectrometer and a PFP chromatographic column to obtain a chromatogram of each standard solution containing a standard substance and an internal standard substance of each branched chain amino acid with the known concentration; carrying out fitting based on the chromatogram of each standard solution to obtain a standard curve equation of each branched chain amino acid; adding the mixed internal standard working solution into a blood sample obtained by treating at least 0.2 mL of to-be-detected blood, adding a protein precipitation reagent, carrying out vortex mixing, carrying out centrifuging to obtain a supernatant, diluting the supernatant, carrying out vortex mixing again, and then taking the supernatant to obtain a to-be-detected sample; detecting the to-be-detected sample to obtain a chromatogram; and then calculating the contents of leucine, isoleucine and valine in the blood sample according to the chromatogram of the to-be-detected sample and each standard curve equation. The sample pretreatment is simple; the time is saved; and the operation becomes rapid.
Owner:BEIJING HARMONY HEALTH MEDICAL DIAGNOSTICS CO LTD

Application of pedf-derived short peptides in the treatment of osteoarthritis

InactiveUS20210221862A1Treating and preventing osteoarthritisPromoting chondrogenesisPeptide/protein ingredientsSkeletal disorderEpitheliumArginine
A method for treating and / or preventing osteoarthritis includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.
Owner:BRIM BIOTECH INC

Application of pedf-derived short peptides in tendon healing

A method for treating a tendon injury includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF), and wherein the variant of the PDSP contains serine-93, alanine-96, glutamine-98, isoleucine-103, isoleucine-104, and arginine 106 of the PDSP and contains one or more amino acid substitutions at other positions, wherein residue location numbers are based on those in the human PEDF.
Owner:BRIM BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products